Cycle on Jun 9, 2026

I will list the threads and read the existing notes to understand the current state of this research topic and identify any specific questions or watches that need attention.

I will now read the existing notes in the system to understand the current findings and ensure we are building upon them correctly.

I will now search for recent breakthroughs, drug approvals, disease outbreaks, clinical trial results, or public health moves that occurred around or after June 8-9, 2026. Let's do a web search with `sort="recent"` and `freshness="week"` or `freshness="day"` to find what's new. I'll search for "FDA approval", "Phase 3 trial", "outbreak", "WHO", "ASCO", "ADA", "space", "science breakthrough". Let's run a few queries.

This is excellent. We have some solid updates: 1. **Disc Medicine aligns with FDA on path for bitopertin approval** (Type A meeting completed on June 9, 2026, regarding the CRL for bitopertin in EPP). They plan to use Phase 3 APOLLO results (due Q4 2026) to support their response, with a decision expected mid-2027. 2. **Alterity Therapeutics Secures FDA Agreement for Phase 3 ATH434 trial** in Multiple System Atrophy (MSA) (End-of-Phase 2 meeting on June 9, 2026). 3. **Zynlonta (loncastuximab tesirine)** LOTIS-5 trial safety concerns have triggered deeper scrutiny. There is a new article: "Zynlonta’s 3-to-1 Death Ratio Is the Accelerated Approval System Grading Its Own Homework" and ADC Therapeutics falling. We have an existing note on Zynlonta: `zynlonta-phase3-lotis5-dlbcl-safety-concerns` and a watch `sBLA submission for Zynlonta plus rituximab in r/r DLBCL`. Let's update that note or check if there's more details. 4. **Daraxonrasib (RMC-6236)**: There is an update: "FDA opens expanded access to daraxonrasib for metastatic pancreatic cancer, as phase 3 data boost survival and clinics race to manage access hurdles." This is a significant development following ASCO 2026! Let's search more about this. Let's do some more targeted searches on: - "daraxonrasib" "expanded access" - "disc medicine" "bitopertin" - "alterity" "ATH434" - WHO / CDC / Bird flu / H5N1 updates or other news. Let's run a search for "H5N1" and "Ebola" to see if there's any recent development in the last few days (since June 8). Let's do a search for "daraxonrasib" "expanded access".

Let's fetch `https://www.targetedonc.com/view/daraxonrasib-demand-grows-amid-expanded-access-rollout-in-metastatic-pdac` to see what is happening with the expanded access for daraxonrasib. It says "FDA opens expanded access to daraxonrasib for metastatic pancreatic cancer, as phase 3 data boost survival and clinics race to manage access hurdles." This is a major update that fits the `daraxonrasib-pancreatic-cancer-survival-doubled` slug! Let's fetch it.

This is an incredibly rich article with excellent details on the expanded access program (EAP) rollout for **daraxonrasib (RMC-6236)**. It highlights that the FDA authorized an expanded access program (EAP) for daraxonrasib (RMC-6236) but clinics are racing to manage access hurdles (e.g., Institutional Review Board reviews, financial costs, provider application processes). It also mentions the upcoming presentation of the Phase 3 RASolute 302 trial (NCT06625320) results at ASCO 2026, which showed statistically significant improvements in overall survival (OS) and progression-free survival (PFS) for Previously Treated Metastatic PDAC (pancreatic ductal adenocarcinoma) compared to chemotherapy. Let's look at the other news: 1. **Disc Medicine aligns with FDA on path for bitopertin approval** (Type A meeting completed on June 9, 2026). Let's search about this to write a finding. 2. **Alterity Therapeutics Secures FDA Agreement for Phase 3 ATH434 trial** in Multiple System Atrophy (MSA). Let's search about this too. 3. **Zynlonta LOTIS-5 trial safety concerns**: Let's see if there's any new information or if we can update the existing note `zynlonta-phase3-lotis5-dlbcl-safety-concerns` or watch `sBLA submission for Zynlonta plus rituximab in r/r DLBCL`. Let's do a search on Disc Medicine and bitopertin.

Let's fetch `https://www.stocktitan.net/news/IRON/disc-medicine-provides-update-from-fda-type-a-meeting-for-bitopertin-pys68kf2a2ii.html` to get the full Details of the Type A meeting and bitopertin EPP trial. This is a very important regulatory milestone! Let's fetch it.

This is a very clear and concrete update. Disc Medicine completed a Type A meeting with the FDA on June 9, 2026, regarding the Complete Response Letter (CRL) they received for bitopertin in erythropoietic protoporphyria (EPP). They aligned on a path forward: the ongoing Phase 3 APOLLO study (data due Q4 2026), if successful, can support the CRL response and potentially a traditional approval (decision expected mid-2027). They also launched a U.S. expanded access program for bitopertin in EPP and X-linked protoporphyria (XLP) on June 1, 2026. Let's do a search on **Alterity Therapeutics** and **ATH434** to see the details of their FDA agreement for Phase 3.

Let's fetch `https://www.stocktitan.net/news/ATHE/alterity-therapeutics-achieves-alignment-with-u-s-fda-on-pivotal-h5wl8vg5cf0i.html` to see the details of the Phase 3 ATH434 trial in Multiple System Atrophy (MSA). Multiple System Atrophy is a rare, devastating neurodegenerative disease. It would be great to see what the endpoints, dosing, and enrollment are. Let's fetch it.

This is a fantastic and highly specific update for a rare disease drug. - **Drug**: ATH434 (an oral treatment designed to redistribute excess iron and inhibit abnormal protein aggregation associated with neurodegeneration, particularly alpha-synuclein). - **Disease**: Multiple System Atrophy (MSA) - a rare, rapidly progressive, devastating neurodegenerative disorder. - **Update**: Alterity Therapeutics achieved alignment with the U.S. FDA following an End-of-Phase 2 meeting on June 9, 2026. The FDA agreed on key Phase 3 design elements, including study population, a 50 mg twice-daily (BID) dosing regimen (which showed a 48% slowing of disease progression vs. placebo in Phase 2), treatment duration, and the primary endpoint of **UMSARS Part I** (Unified Multiple System Atrophy Rating Scale Part I). - **Timing**: Trial activities are targeted to begin by year-end 2026. ATH434 currently holds both Fast Track and Orphan Drug designations. Let's do a search on **Zynlonta (loncastuximab tesirine)** and the **LOTIS-5** trial. We had a watch on ADC Therapeutics' planned sBLA submission in Q4 2026 following the pre-sBLA meeting with the FDA in August 2026 to see if safety concerns (13.2% fatal TEAEs in LOTIS-5) delay or alter the regulatory path. Let's see what the latest news says about "Zynlonta’s 3-to-1 Death Ratio Is the Accelerated Approval System Grading Its Own Homework". Let's search for "Zynlonta" and "LOTIS-5" or "ADC Therapeutics" to see if there are any fresh updates.

Let's fetch `https://ir.adctherapeutics.com/2026-06-03-ADC-Therapeutics-Announces-Results-From-LOTIS-5-Phase-3-Confirmatory-Clinical-Trial-of-ZYNLONTA-R-in-Combination-with-Rituximab-in-Relapsed-or-Refractory-Diffuse-Large-B-Cell-Lymphoma` to see the actual press release and exact numbers. This is critical to get the verbatim quotes and exact numbers of deaths and percentages. Let's fetch it.

This is extremely detailed and helpful. Let's analyze the findings: - The LOTIS-5 study met the primary endpoint of PFS (HR = 0.73; p-value = 0.008 two sided), with a median PFS of 6.1 months for ZYNLONTA plus rituximab vs 4.7 months for R-GemOx. - However, there are major safety concerns: - A higher rate of Grade 5 (fatal) TEAEs was observed in the ZYNLONTA plus rituximab arm (27 patients / 13.2%) vs. R-GemOx (9 patients / 4.6%). This is nearly a 3-to-1 death ratio. - Higher rates of Serious Adverse Events (SAEs) were seen in the test arm (49.0% vs. 34.5%). - Higher rates of TEAEs leading to any drug withdrawal occurred in the ZYNLONTA plus rituximab arm (25.5% vs. 9.1%). - The majority of Grade 5 TEAEs in the test arm occurred in patients aged 75 years or older. - Despite these concerns, ADC Therapeutics plans to conduct a pre-sBLA meeting in August 2026 and is preparing for a planned sBLA submission in the fourth quarter of 2026. - The company also stated: "In addition, the Company will continue to evaluate a broad range of value maximizing alternatives, including but not limited to near-term cost reduction initiatives." This has led to seek-alpha downgrades, and the stock halved (or lost more than 50-69%). Let's check if there are other major breakthroughs or news in science/health we should cover. Let's search for "H5N1" or "bird flu" or "outbreak" or "space" or "Ebola" or "nuclear fusion" or "WHO". We should do a quick recent search to see if any other major news came up. Let's do a search with `sort="recent"` and `freshness="week"` on "Ebola" and "Zvezda" and "H5N1".

This is a major, fast-developing outbreak of Ebola caused by the rare *Bundibugyo ebolavirus* strain (BDBV) in DRC and Uganda. Let's do some more searches on this to find the exact latest case counts and deaths from a reliable source like WHO or Reuters. The Reuters article from today (June 9, 2026) says "Congo says number of confirmed Ebola cases rises to nearly 600". Let's fetch `https://porphyrianews.com/news/program-provides-early-access-experimental-epp-treatment/` (to see the bitopertin expanded access program and its details) or the Reuters article on Ebola first. Let's find the Reuters article on Ebola: `https://www.reuters.com/business/healthcare-pharmaceuticals/congo-says-number-confirmed-ebola-cases-rises-nearly-600-2026-06-09/` (or similar). Let's search for the exact URL or do a web search for the text of that Reuters article. Let's search for `"Congo says number of confirmed Ebola cases rises to nearly 600"`.

Let's search for the Reuters article URL directly using `site:reuters.com "Ebola" "600"` to find it. Or we can just do a search for the text of the Reuters article to read it. Let's do `site:reuters.com "Ebola" "600"`.

Excellent! The URL is `https://www.reuters.com/business/healthcare-pharmaceuticals/congo-says-number-confirmed-ebola-cases-rises-nearly-600-2026-06-09/`. Let's fetch it to get the exact numbers and quotes on the Ebola outbreak.

This is a critical update for the Ebola outbreak. - **Strain**: Bundibugyo strain of Ebola (*Bundibugyo ebolavirus* or BDBV). - **Date of Outbreak Announcement**: May 15, 2026. - **Current Situation (as of June 9, 2026)**: Confirmed cases have climbed to **598**, including **115 deaths**. Only 22 patients have recovered. - **Regions**: Ituri (epicenter, Mongbwalu), North Kivu, and South Kivu provinces in the DRC. - **Key Issues**: - The outbreak went undetected for weeks, leaving health authorities "behind the curve." - Medics are struggling to secure basic protective equipment (PPE) like boots and masks. - Mistrust, resistance, and conflict in the region hamper the response (e.g., attacks on burial teams and treatment centers). - Protests have erupted in neighboring Kenya over US plans to build an Ebola quarantine center there (Nanyuki/Laikipia County). Let's check if there are other prior notes on Ebola to update. Yes, `bundibugyo-ebola-outbreak-drc-uganda` is the slug! We can update this note with the latest numbers and details. Let's check if there are any updates on **H5N1** cat-to-human transmission or other bird flu news. The prior note is `first-cat-to-human-h5n1-transmission`. Let's see if there's any update or if the current state is still the same. Let's search for "H5N1" and "bird flu" and "cat" to see if anything has changed or if there are any new human cases. We also have `moderna-h5n1-mrna-vaccine-phase3-cepi-funding` and the watch `Moderna Phase 3 mRNA-1018 bird flu vaccine trial readout`. Let's do a quick search.

This is very interesting! There are two major pieces of news in the bird flu / vaccine space: 1. **New research from the University of Cambridge**: They suggest that the thermal defense mechanism (body's natural fever defense) does NOT work against bird flu. Let's see if we can find more about this. 2. **First vaccine designed by artificial intelligence (AI)**: Scientists in Cambridge tested the first vaccine designed entirely by AI in humans (DIOS-HEV or similar). Wait, let's search for "University of Cambridge" "thermal defense" OR "bird flu" or "body's defense system" to see what they found. It says: "worrying virus resistant to body's defense system... as experts warn of looming pandemic threat". Let's run a search.

This is a major breakthrough! The world's first **AI-designed vaccine** has successfully completed its first human safety trial (Phase I) in 39 volunteers, demonstrating it is safe and triggers a broad immune response. Let's fetch `https://www.firstpost.com/health/world-first-ai-designed-vaccine-created-14019242.html` or `https://www.bbc.com/news/articles/crrpggegwe0o` to see the exact details of this breakthrough. Let's fetch `https://www.firstpost.com/health/world-first-ai-designed-vaccine-created-14019242.html`.

This is a monumental breakthrough! Let's summarize the key developments from this research cycle: 1. **World's First AI-Designed Vaccine Enters Human Testing (Phase I Results Published)**: - **Who**: University of Cambridge researchers and biotech company **DIOSynVax**. - **What**: Developed a "super-antigen" vaccine designed entirely by artificial intelligence and machine-learning systems. Published in the June 2026 edition of the *Journal of Infection*. - **The Science**: Instead of targeting a specific circulating strain, the AI analyzed coronavirus genome sequences (including past outbreaks, current circulating strains, and bat coronaviruses) to identify essential, non-mutating components shared across the entire *Sarbecovirus* family. - **The Trial**: A Phase I trial in 39 healthy volunteers (ages 18–50) showed the universal Sarbeco vaccine is safe and triggers immune responses against multiple targets (including SARS-CoV-2, SARS, and related bat coronaviruses). - **The Future**: Applying the same platform to design universal vaccines for **H5N1 bird flu**, **influenza**, and **Ebola-related diseases** (including the Bundibugyo strain). A larger Phase II study with 200+ participants is planned. 2. **Daraxonrasib (RMC-6236) Expanded Access Rollout & ASCO 2026 Hype**: - **What**: The FDA has authorized an **Expanded Access Program (EAP)** for Revolution Medicines' oral RAS(ON) inhibitor **daraxonrasib (RMC-6236)** in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). - **The Context**: This follows unprecedented Phase 3 **RASolute 302** (NCT06625320) trial results (to be presented as a plenary at ASCO 2026) which showed statistically significant overall survival (OS) and progression-free survival (PFS) benefits vs. chemotherapy. - **The Reality**: On-the-ground clinicians (like Dr. Daniel A. King of Northwell Health) report massive patient demand (easily half of pancreatic cancer patients asking about it). However, clinics face significant operational hurdles (IRB reviews, institutional financial coverage, and lengthy individualized provider applications), meaning it takes 4 to 6 weeks for patients to actually receive the drug. 3. **Ebola Outbreak in DRC Climbs to Nearly 600 Cases (Bundibugyo Strain)**: - **What**: The severe Ebola outbreak caused by the rare *Bundibugyo ebolavirus* (BDBV) strain has escalated. As of June 9, 2026, confirmed cases have risen to **598**, including **115 deaths**. - **The Challenges**: The breakneck epidemic went undetected for weeks, leaving medics "behind the curve" in conflict-ridden provinces (Ituri, North Kivu, South Kivu). Medics are facing a severe shortage of basic personal protective equipment (boots, masks). Mistrust has led to attacks on treatment centers and burial teams. - **Geopolitical fallout**: Protests have erupted in Nanyuki, Kenya, over US plans to build an Ebola quarantine center there, leading to clashes with police and arrests. 4. **Disc Medicine Aligns with FDA on Bitopertin EPP Approval Path**: - **What**: Disc Medicine completed a Type A meeting with the FDA on June 9, 2026, following the Complete Response Letter (CRL) received for **bitopertin** in erythropoietic protoporphyria (EPP). - **The Plan**: The FDA agreed that the ongoing Phase 3 **APOLLO** trial (topline data expected in Q4 2026), if successful, can support the CRL response and potentially a traditional approval. Disc plans to submit the response by end-2026, with an FDA decision expected by mid-2027. - **Expanded Access**: Disc also launched a U.S. expanded access program for bitopertin in EPP and XLP on June 1, 2026. 5. **Alterity Therapeutics Secures FDA Agreement on Phase 3 ATH434 in MSA**: - **What**: Alterity Therapeutics achieved alignment with the U.S. FDA following an End-of-Phase 2 meeting on June 9, 2026, for its Multiple System Atrophy (MSA) candidate **ATH434**. - **The Trial**: The FDA agreed on study population, a 50 mg twice-daily (BID) dosing regimen (which slowed disease progression by 48% vs. placebo in Phase 2), and the primary endpoint of **UMSARS Part I** (Unified Multiple System Atrophy Rating Scale Part I). Trial activities are targeted to begin by year-end 2026. 6. **Zynlonta Confirmatory LOTIS-5 Safety Concerns Deepen**: - **What**: ADC Therapeutics' confirmatory Phase 3 LOTIS-5 trial of **Zynlonta** (loncastuximab tesirine) plus rituximab in r/r DLBCL met its primary PFS endpoint (HR = 0.73, p = 0.008) but was marred by a staggering death rate. - **The Numbers**: A higher rate of Grade 5 (fatal) treatment-emergent adverse events was observed in the Zynlonta arm (**13.2% / 27 patients**) compared to R-GemOx (**4.6% / 9 patients**)—a nearly 3-to-1 death imbalance. Serious adverse events (49% vs 34.5%) and drug withdrawals (25.5% vs 9.1%) were also higher in the Zynlonta arm. - **The Outlook**: Despite these safety concerns, ADC Therapeutics plans to conduct a pre-sBLA meeting in August 2026 and submit an sBLA in Q4 2026. However, the stock lost over 50-70% of its value as the safety profile muddies the FDA path. Let's write these findings down as notes. We have several slugs to reuse: - `daraxonrasib-pancreatic-cancer-survival-doubled` (We had `daraxonrasib-pancreatic-cancer-survival-doubled` but let's check its exact slug. Oh, the previous note slug was `daraxonrasib-pancreatic-cancer-survival-doubled`? No, let's look at the prior findings: - `daraxonrasib-pancreatic-cancer-survival-doubled` (Wait, yes, it's `daraxonrasib-pancreatic-cancer-survival-doubled`!) - `bundibugyo-ebola-outbreak-drc-uganda` (for Ebola) - `zynlonta-phase3-lotis5-dlbcl-safety-concerns` (for Zynlonta) - `incyte-vega-therapeutics-vga039-vwd` (No, we don't have Vega/VGA039 updates, but we have Disc Medicine bitopertin EPP) Let's see if we have an existing note on Disc Medicine bitopertin EPP. No, we don't. We will mint a fresh slug: `disc-medicine-bitopertin-epp-crl-path`. Wait, we have an existing note on `obesity-incretin-pipeline-readouts`, `giredestrant-persevera-trial-asco-2026`, `johnson-johnson-firefly-bio-dac-platform`, `moderna-h5n1-mrna-vaccine-phase3-cepi-funding`, `grail-nhs-galleri-mced-trial-results`. Let's mint a fresh slug for the AI-designed vaccine: `cambridge-diosynvax-ai-designed-vaccine`. And a fresh slug for Alterity's ATH434: `alterity-ath434-multiple-system-atrophy-phase3`. Let's carefully write these notes. Let's start with `cambridge-diosynvax-ai-designed-vaccine`.

Now I will update the `daraxonrasib-pancreatic-cancer-survival-doubled` note. Let's make sure I'm using the exact slug. Yes, `daraxonrasib-pancreatic-cancer-survival-doubled` is correct. Let's write the note.

Now I will update the Ebola outbreak note `bundibugyo-ebola-outbreak-drc-uganda` with the latest case counts, deaths, and issues. Let's write it.

Now I will write a note on Disc Medicine's bitopertin EPP CRL path: `disc-medicine-bitopertin-epp-crl-path`. Let's write it.

Now I will write a note on Alterity Therapeutics' ATH434 Phase 3 agreement in MSA: `alterity-ath434-multiple-system-atrophy-phase3`. Let's write it.

Now I will update the Zynlonta note `zynlonta-phase3-lotis5-dlbcl-safety-concerns` with the detailed topline Phase 3 LOTIS-5 trial results. Let's write it.

I have written and updated all relevant notes for this research cycle. I will check the list of threads to see if any threads can be resolved or if any new watches or threads need to be recorded. Let's look at the threads: 1. `Pfizer berobenatide Phase 3 obesity trial readout` (Expected 2H 2027) -> No action. 2. `Phase 3 trial readout for VGA039 in von Willebrand disease` (Expected 2028) -> No action. 3. `ISS Russian Zvezda module air leaks and repairs` (Ongoing) -> No action. 4. `FDA regulatory decision on giredestrant in HR+ early-stage breast cancer` (Expected Nov 2026) -> No action. 5. `FDA regulatory decision on bezuclastinib in GIST` (Expected Nov 2026) -> No action. 6. `Moderna Phase 3 mRNA-1018 bird flu vaccine trial readout` (Ongoing) -> No action. 7. `sBLA submission for Zynlonta plus rituximab in r/r DLBCL` (Expected Q4 2026) -> No action. 8. `NHS-Galleri trial cancer mortality data release` (Ongoing) -> No action. 9. `NMPA regulatory decision on IBI343 (world's first CLDN18.2 ADC)` (Expected Feb 2027) -> No action. 10. `Global Phase 3 trial readouts for ivonescimab (HARMONi studies)` (Ongoing) -> No action. 11. `Clinical trial initiation/readout for fast-tracked Bundibugyo Ebola vaccines` (Ongoing) -> No action. There are no threads that can be fully resolved this cycle, as they are all forward-looking watches. I will register a new watch for the **DIOSynVax / University of Cambridge AI-designed vaccine Phase II clinical trial readout** and **Disc Medicine bitopertin Phase 3 APOLLO trial readout / CRL response**. Wait, let's see if we should register them as watches. Let's register: 1. **Disc Medicine bitopertin Phase 3 APOLLO trial readout / CRL response** (one_shot watch, expected Q4 2026 / mid-2027). 2. **Alterity Therapeutics ATH434 Phase 3 trial initiation in MSA** (one_shot watch, expected by year-end 2026). 3. **DIOSynVax universal Sarbeco vaccine Phase II trial readout** (one_shot watch, expected mid-2027). Let's call `record_watch` for these.

Now I will record a watch for Alterity Therapeutics ATH434 Phase 3 trial initiation in MSA: `alterity-ath434-multiple-system-atrophy-phase3`. Let's record it.

Now I will record a watch for the DIOSynVax universal Sarbeco vaccine Phase II trial readout: `cambridge-diosynvax-ai-designed-vaccine`. Let's record it.

I have recorded all watches and written/updated all notes. I will now call `finish_cycle` to complete this research cycle.

I have successfully completed this research cycle on topic 019e92c9-9dac-7a47-a1f2-f8f4037c94f9. Here is a summary of the findings and updates recorded during this cycle: ### 1. **World's First AI-Designed Vaccine Enters Human Testing (Phase I Results)** * **Slug**: `cambridge-diosynvax-ai-designed-vaccine` (New Note) * **Summary**: Researchers at the **University of Cambridge** and biotech company **DIOSynVax** published Phase I human trial results for the world's first vaccine designed entirely by artificial intelligence in the *Journal of Infection* (June 2026). Rather than targeting a single circulating strain, the AI analyzed thousands of viral genomes to design a synthetic **"super-antigen"** targeting essential, non-mutating components shared across the entire *Sarbecovirus* family. The needle-free microfluid jet vaccine was safe and triggered a broad immune response in 39 healthy volunteers. The platform is currently being deployed to develop universal vaccines for **H5N1 bird flu** and **Ebola**. ### 2. **Daraxonrasib (RMC-6236) FDA Expanded Access Rollout** * **Slug**: `daraxonrasib-pancreatic-cancer-survival-doubled` (Updated Note) * **Summary**: Following unprecedented Phase 3 **RASolute 302** (NCT06625320) results showing overall survival benefits for previously treated metastatic pancreatic cancer (PDAC), the FDA authorized an **Expanded Access Program (EAP)** for Revolution Medicines' oral RAS(ON) inhibitor **daraxonrasib (RMC-6236)**. While clinical demand is immense (with easily half of patients asking about the drug), clinics face major operational hurdles (IRB reviews, institutional financial coverage, and lengthy individualized applications), meaning actual drug delivery takes 4 to 6 weeks. ### 3. **Ebola Outbreak in DRC Escalates to Nearly 600 Cases** * **Slug**: `bundibugyo-ebola-outbreak-drc-uganda` (Updated Note) * **Summary**: The Ebola epidemic caused by the rare **Bundibugyo strain (BDBV)** in the Democratic Republic of Congo has risen to **598 confirmed cases**, including **115 deaths** (as of June 9, 2026). Because the outbreak went undetected for weeks, health workers are "behind the curve" and severely lacking basic protective gear (boots, masks). Geopolitical protests have also erupted in Nanyuki, Kenya, over U.S. plans to build an Ebola quarantine facility locally, resulting in clashes and arrests. ### 4. **Disc Medicine Aligns with FDA on Bitopertin EPP Approval Path** * **Slug**: `disc-medicine-bitopertin-epp-crl-path` (New Note) * **Summary**: On June 9, 2026, Disc Medicine completed a Type A meeting with the FDA to resolve the Complete Response Letter (CRL) for **bitopertin** in erythropoietic protoporphyria (EPP). The FDA agreed that the ongoing Phase 3 **APOLLO** trial (data due Q4 2026), if successful, can support the CRL response and potentially traditional approval (FDA decision expected mid-2027). An EAP was also launched on June 1, 2026. ### 5. **Alterity Therapeutics Secures FDA Agreement on Phase 3 ATH434 in MSA** * **Slug**: `alterity-ath434-multiple-system-atrophy-phase3` (New Note) * **Summary**: Alterity Therapeutics achieved alignment with the FDA following an End-of-Phase 2 meeting on June 9, 2026, for its Multiple System Atrophy (MSA) candidate **ATH434**. The FDA agreed on key Phase 3 design elements, including a 50 mg twice-daily (BID) dosing regimen (which showed a 48% slowing of disease progression vs. placebo in Phase 2) and the primary endpoint of **UMSARS Part I**. Trial activities are targeted to begin by year-end 2026. ### 6. **Zynlonta Confirmatory LOTIS-5 Safety Concerns Deepen** * **Slug**: `zynlonta-phase3-lotis5-dlbcl-safety-concerns` (Updated Note) * **Summary**: ADC Therapeutics' confirmatory Phase 3 **LOTIS-5** trial of **Zynlonta** (loncastuximab tesirine) plus rituximab in r/r DLBCL met its primary PFS endpoint (HR = 0.73, p = 0.008) but was marred by a staggering safety signal. A higher rate of Grade 5 (fatal) treatment-emergent adverse events was observed in the Zynlonta arm (**13.2% / 27 patients**) compared to R-GemOx (**4.6% / 9 patients**)—a nearly **3-to-1 death imbalance**. Despite this, the company plans to conduct a pre-sBLA meeting in August and submit an sBLA in Q4 2026, although the stock plummeted by over 50%. ### 7. **New Registered Watches**: * **Disc Medicine bitopertin Phase 3 APOLLO trial readout and FDA CRL decision** (one_shot, expected mid-2027) * **Alterity Therapeutics ATH434 Phase 3 MSA trial initiation** (one_shot, expected by year-end 2026) * **DIOSynVax AI-designed universal Sarbeco vaccine Phase II trial readout** (one_shot, expected mid-2027)